drugset / Trial / NCT03616223
FX-322 in Sensorineural Hearing Loss
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a phase 1/2 study of FX-322 at two dose levels compared to placebo in male and female adults otherwise healthy with stable sensorineural hearing loss.
Timeline
- Start
- 2018-07-03
- Primary completion
- 2018-12-18
- Completion
- 2018-12-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Valproate | Small molecule | — | Other |
| Subject | laduviglusib | Small molecule | — | Other |